Related Experiment Video

Updated: Jun 14, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

842

Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors

Astero Klampatsa1

  • 1Thoracic Oncology Immunotherapy Group, The Institute of Cancer Research, Division of Cancer Therapeutics, London, UK.

Expert Opinion on Biological Therapy
|August 30, 2024
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CAR-T bystander effectsCAR-T cell therapyantigen densityendogenous immune responseepitope spreadingsolid cancertumor antigen heterogeneity

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493